Bevacizumab/Chemo Combination Approved for Treating Metastatic Colorectal Cancer

Publication
Article
OncologyONCOLOGY Vol 20 No 8
Volume 20
Issue 8

Genentech Inc, recently announced that the US Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with intravenous fluorouracil (5-FU)-based chemotherapy for second-line metastatic colorectal cancer.

Genentech Inc, recently announced that the US Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with intravenous fluorouracil (5-FU)-based chemotherapy for second-line metastatic colorectal cancer. Bevacizumab is also approved as a first-line treatment of metastatic colorectal cancer (CRC) in combination with intravenous 5-FU-based chemotherapy.

The approval is based on results of a randomized, controlled, multicenter phase III trial (E3200) of 829 patients with advanced or metastatic CRC who had received previous treatment with irinotecan and 5-FU as initial therapy for metastatic disease or as adjuvant therapy. The study showed that patients who received bevacizumab plus the 5-FU-based chemotherapy regimen known as FOLFOX4 (oxaliplatin [Eloxatin]/5‑FU/leucovorin) had a 25% reduction in the risk of death (hazard ratio = 0.75), the primary endpoint, which is equivalent to a 33% improvement in overall survival, compared to patients who received FOLFOX4 alone. Median survival for patients receiving bevacizumab plus FOLFOX4 was 13.0 months, compared to 10.8 months for those receiving FOLFOX4 alone.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content